Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): A multicentre, double-blind, randomised, phase 2b dose-selection study

dc.date.accessioned2022-01-04T20:31:44Z
dc.date.accessioned2022-10-25T18:47:59Z
dc.date.available2022-01-04T20:31:44Z
dc.date.available2022-10-25T18:47:59Z
dc.date.created2022-01-04T20:31:44Z
dc.date.issued2014
dc.identifierhttps://hdl.handle.net/20.500.12866/10583
dc.identifierLancet
dc.identifierhttps://doi.org/10.1016/S0140-6736(13)62568-4
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4785074
dc.description.abstractClinical effectiveness of previous regimens to treat Plasmodium vivax infection have been hampered by compliance. We aimed to assess the dose–response, safety, and tolerability of single-dose tafenoquine plus 3-day chloroquine for P vivax malaria radical cure.
dc.languageeng
dc.publisherElsevier
dc.relationurn:issn:1474-547X
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectHumans
dc.subjectPeru
dc.subjectTreatment Outcome
dc.subjectIndia
dc.subjectBrazil
dc.subjectDrug Therapy, Combination
dc.subjectDouble-Blind Method
dc.subjectDose-Response Relationship, Drug
dc.subjectThailand
dc.subjectAminoquinolines
dc.subjectAntimalarials
dc.subjectChloroquine
dc.subjectMalaria
dc.subjectPrimaquine
dc.subjectSecondary Prevention
dc.titleTafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): A multicentre, double-blind, randomised, phase 2b dose-selection study
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución